Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

about

Contrary melanoma-associated antigen-A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma

P2860

Q41198162-B8339199-3990-45F5-8315-178026FF8698

P2860

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

Item

http://www.wikidata.org/entity/Q38815481

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Melanoma-associated antigen ex ...... itors in head and neck cancer.

@en

type

Item

label

Melanoma-associated antigen ex ...... itors in head and neck cancer.

@en

prefLabel

Melanoma-associated antigen ex ...... itors in head and neck cancer.

@en

P1476

Melanoma-associated antigen ex ...... bitors in head and neck cancer

@en

P2093

Alexander C Kübler

http://www.w3.org/2001/XMLSchema#string

Andreas Fuchs

http://www.w3.org/2001/XMLSchema#string

Christian Linz

http://www.w3.org/2001/XMLSchema#string

Nora Küchler

http://www.w3.org/2001/XMLSchema#string

Roman C Brands

http://www.w3.org/2001/XMLSchema#string

P2860

MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

Cancer/testis antigens, gametogenesis and cancer

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.

Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma.

The cancer/testis genes: review, standardization, and commentary.

Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?

Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

P304

1211-1217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2015.3345

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Urs Müller-richter

S Hartmann

P577

2015-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280304543

http://www.w3.org/2001/XMLSchema#string

P698

26622654

http://www.w3.org/2001/XMLSchema#string

P932

4509046

http://www.w3.org/2001/XMLSchema#string

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

about

P2860

P2860

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932